Loading
A phase 3 trial of Oxaliplatin, Doxorubicin, Cisplatin and Raltitrexed in Hepatocellular carcinoma, run by Zhujiang Hospital, with a status the registry has not verified recently.
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial is a phase 3 interventional study registered as NCT05701436 by Zhujiang Hospital, with 144 participants planned, started 2022-09-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed. Conditions recorded: Liver, Cancer of, Primary Resectable.
Linked to the drug Raltitrexed because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares Raltitrexed, Oxaliplatin, Doxorubicin, Cisplatin and the tag pipeline.
Shares Raltitrexed and the tag pipeline.
Shares Cisplatin, Hepatocellular carcinoma and the tag pipeline.
Shares Doxorubicin, Hepatocellular carcinoma and the tag pipeline.
Shares Oxaliplatin, Cisplatin and the tag pipeline.
Shares Oxaliplatin, Cisplatin and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Oxaliplatin, Cisplatin and the tag pipeline.